Dr. Mona-gekanju Toeque, M.D.,MPH
Infectious Disease (Infectious Disease Physician)
4905 Hollywood Blvd
Los Angeles, CA 90027
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 92
Licensed in California since 2021, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CA license A173822 (first issued 2021; current) · NV license 29289 · WA license MD.MD.70083809 (first issued 2026; active) -
Internal Medicine Physician
CA license A173822 (first issued 2021; current) · NV license 29289
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Aids Healthcare Foundation (101 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 92
- Services billed
- 418
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 128 | 63 |
| Established patient office or other outpatient visit, 20-29 minutes | 66 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 31 |
| Established patient office or other outpatient visit, 10-19 minutes | 18 | 17 |
| Established patient office or other outpatient visit, 40-54 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Los Angeles, CA | 310 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 281 |
| Gabapentin Other prescribers in Los Angeles, CA | 145 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 120 |
| Amlodipine Besylate Other prescribers in Los Angeles, CA | 110 |
| Metformin Hcl Other prescribers in Los Angeles, CA | 104 |
| Rosuvastatin Calcium Other prescribers in Los Angeles, CA | 103 |
| Genvoya (elviteg/cob/emtri/tenof alafen) | 98 |
| Lisinopril Other prescribers in Los Angeles, CA | 91 |
| Prezcobix (darunavir/cobicistat) | 91 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 18 payments worth $467 in total to this clinician.
| Viiv Healthcare Company | $148 |
|---|---|
| Gilead Sciences, Inc. | $129 |
| Merck Sharp & Dohme LLC | $113 |
| Theratechnologies Inc. | $29.60 |
| GlaxoSmithKline, LLC. | $28.40 |
| Exact Sciences Corporation | $19.15 |
| Food and Beverage | $467 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $14,494 in research payments for these studies, mostly to the institutions running them.
- M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of…
AbbVie Inc. - A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
AbbVie Inc. · Terminated · NCT06032546 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
AbbVie Inc. · Completed · NCT04903626
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.